Therefore, the therapeutic strategies of wedelolactone to decrease NLRP3 activity and target the pyroptosis could be useful for treating NLRP3‐driven diseases, such as gout, cancer, type 2 diabetes, Alzheimer's, Parkinson's and cardiovascular diseases.30, 43, 44. This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.